Article
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.
Nature biotechnology - 1 Nov 2000
Shanafelt A B, Lin Y, Shanafelt M C, Forte C P, Dubois-Stringfellow N, Carter C, Gibbons J A, Cheng S L, Delaria K A, Fleischer R, Greve J M, Gundel R, Harris K, Kelly R, Koh B, Li Y, Lantz L, Mak P, Neyer L, Plym M J, Roczniak S, Serban D, Thrift J, Tsuchiyama L, Wetzel M, Wong M, Zolotorev A
Abstract excerpt
Human interleukin 2 (IL-2; Proleukin) is an approved therapeutic for advanced-stage metastatic cancer; however, its use is restricted because of severe systemic toxicity. Its function as a central mediator of T-cell activation may contribute to its efficacy for cancer therapy. However, activation of natural killer (NK) cells by therapeutically administered IL-2 may mediate toxicity. Here we have used targeted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.